Caroline Chaul-Barbosa1, Daniel Fernandes Marques2. 1. Sirian-Libanese Hospital, Sao Paulo, SP, Brazil. caroline.clbarbosa@hsl.org.br. 2. Sirian-Libanese Hospital, Brasilia, DF, Brazil.
Abstract
PURPOSE OF REVIEW: Recurrent glioblastoma (rGBM) has no standard treatment. Despite a better molecular knowledge, few therapies have brought changes in clinical practice so far. Here we will review the current data evaluating the re-radiation, re-resection, bevacizumab, and cytotoxic chemotherapy agents in this setting. We will also discuss the advances of immunotherapy and the possible benefit of this treatment for patients with rGBM. RECENT FINDINGS: Next-generation sequencing is increasingly utilized in the clinical practice of neuro-oncologists, bringing gene mutations as targets for therapies. As in other solid tumors, immunotherapy has been also extensively studied in rGBM, with interesting results in phase I and II trials. The most promising therapies in the horizon are combinations including immune checkpoint inhibitors, virotherapy, vaccines, and monoclonal antibodies. Although re-radiation, re-resection, bevacizumab, and chemotherapy are still the most widely used therapies for treating rGBM, the clinical benefit from these treatments is still not well established. Preliminary results of studies with immune checkpoint inhibitors were disappointing, but virotherapy emerges as more promising immunotherapy in rGBM, especially in combination with other strategies. In addition to the gain in overall survival, the improvement in the quality of life of these patients is also expected.
PURPOSE OF REVIEW: Recurrent glioblastoma (rGBM) has no standard treatment. Despite a better molecular knowledge, few therapies have brought changes in clinical practice so far. Here we will review the current data evaluating the re-radiation, re-resection, bevacizumab, and cytotoxic chemotherapy agents in this setting. We will also discuss the advances of immunotherapy and the possible benefit of this treatment for patients with rGBM. RECENT FINDINGS: Next-generation sequencing is increasingly utilized in the clinical practice of neuro-oncologists, bringing gene mutations as targets for therapies. As in other solid tumors, immunotherapy has been also extensively studied in rGBM, with interesting results in phase I and II trials. The most promising therapies in the horizon are combinations including immune checkpoint inhibitors, virotherapy, vaccines, and monoclonal antibodies. Although re-radiation, re-resection, bevacizumab, and chemotherapy are still the most widely used therapies for treating rGBM, the clinical benefit from these treatments is still not well established. Preliminary results of studies with immune checkpoint inhibitors were disappointing, but virotherapy emerges as more promising immunotherapy in rGBM, especially in combination with other strategies. In addition to the gain in overall survival, the improvement in the quality of life of these patients is also expected.
Entities:
Keywords:
Immunotherapy in gliomas; Re-irradiation; Recurrent glioblastoma; Virotherapy
Authors: G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi Journal: J Neurooncol Date: 2010-11-05 Impact factor: 4.130
Authors: Andrej Pala; Anne Lea Schmitz; Andreas Knoll; Max Schneider; Michal Hlavac; Ralph König; Christian Rainer Wirtz; Jan Coburger Journal: Clin Neurol Neurosurg Date: 2018-02-05 Impact factor: 1.876
Authors: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Derek R Johnson; Antonio M P Omuro; Arliene Ravelo; Nicolas Sommer; Annie Guerin; Raluca Ionescu-Ittu; Sherry Shi; Alex Macalalad; Joon H Uhm Journal: Curr Med Res Opin Date: 2017-11-10 Impact factor: 2.580
Authors: Thomas Kaley; Mehdi Touat; Vivek Subbiah; Antoine Hollebecque; Jordi Rodon; A Craig Lockhart; Vicki Keedy; Franck Bielle; Ralf-Dieter Hofheinz; Florence Joly; Jean-Yves Blay; Ian Chau; Igor Puzanov; Noopur S Raje; Jurgen Wolf; Lisa M DeAngelis; Martina Makrutzki; Todd Riehl; Bethany Pitcher; Jose Baselga; David M Hyman Journal: J Clin Oncol Date: 2018-10-23 Impact factor: 44.544
Authors: Björn Scheffler; Sied Kebir; Martin Glas; Lazaros Lazaridis; Teresa Schmidt; Christoph Oster; Tobias Blau; Daniela Pierscianek; Jens T Siveke; Sebastian Bauer; Hans-Ulrich Schildhaus; Ulrich Sure; Kathy Keyvani; Christoph Kleinschnitz; Martin Stuschke; Ken Herrmann; Cornelius Deuschl Journal: J Cancer Res Clin Oncol Date: 2022-08-12 Impact factor: 4.322